NCT06602323View on ClinicalTrials.gov

TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

October 1, 2028

Study Completion Date

October 1, 2028

Conditions
Myelodysplastic SyndromesAcute Myeloid Leukemia
Interventions
COMBINATION_PRODUCT

TMLI/Flu/Mel

Targeted total bone marrow and lymphoid irradiation (TMLI) conformal therapy administered in combination with a reduced-intensity regimen based on Fludarabine and Melphalan.

All Listed Sponsors
lead

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

OTHER

NCT06602323 - TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia. | Biotech Hunter | Biotech Hunter